Validation of 3- and 5-point severity scales to assess ARIA-E.
Luc BracoudGregory KleinMarco LyonsMarzia A ScelsiJakub WojtowiczSzofia BullainDerk PurcellJochen B FiebachJerome BarakosJoyce SuhyPublished in: Alzheimer's & dementia (Amsterdam, Netherlands) (2023)
A simple rating scale is needed to rate severity of amyloid-related imaging abnormalities-edema (ARIA-E) in both research and clinical settings.The 3- and 5-point Severity Scales of ARIA-E (SSAE-3/-5) have good inter- and intra-reader agreement.The SSAE-3/-5 have been used in most major Alzheimer's disease (AD) trials to date and are suitable for large-scale use in routine clinical practice, which may help support the expansion of anti-amyloid antibodies as treatment options for AD.